Optimizing patient expectancy in the pharmacologic treatment of major depressive disorder

被引:0
|
作者
Zilcha-Mano, Sigal [1 ]
Brown, Patrick J. [2 ]
Roose, Steven P. [2 ]
Cappetta, Kiley [2 ]
Rutherford, Bret R. [2 ]
机构
[1] Univ Haifa, Dept Psychol, IL-31905 Haifa, Israel
[2] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, New York, NY 10032 USA
关键词
expectancy; major depressive disorder; placebo effects; PLACEBO-RESPONSE; BETWEEN-PERSON; WITHIN-PERSON; METAANALYSIS; DESIGN; ALLIANCE; QUESTION; MODELS;
D O I
10.1017/S0033291718003343
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background Patient expectancy is an important source of placebo effects in antidepressant clinical trials, but all prior studies measured expectancy prior to the initiation of medication treatment. Little is known about how expectancy changes during the course of treatment and how such changes influence clinical outcome. Consequently, we undertook the first analysis to date of in-treatment expectancy during antidepressant treatment to identify its clinical and demographic correlates, typical trajectories, and associations with treatment outcome. Methods Data were combined from two randomized controlled trials of antidepressant medication for major depressive disorder in which baseline and in-treatment expectancy assessments were available. Machine learning methods were used to identify pre-treatment clinical and demographic predictors of expectancy. Multilevel models were implemented to test the effects of expectancy on subsequent treatment outcome, disentangling within- and between-patient effects. Results Random forest analyses demonstrated that whereas more severe depressive symptoms predicted lower pre-treatment expectancy, in-treatment expectancy was unrelated to symptom severity. At each measurement point, increased in-treatment patient expectancy significantly predicted decreased depressive symptoms at the following measurement (B = -0.45, t = -3.04, p = 0.003). The greater the gap between expected treatment outcomes and actual depressive severity, the greater the subsequent symptom reductions were (B = 0.49, t = 2.33, p = 0.02). Conclusions Greater in-treatment patient expectancy is associated with greater subsequent depressive symptom reduction. These findings suggest that clinicians may benefit from monitoring and optimizing patient expectancy during antidepressant treatment. Expectancy may represent another treatment parameter, similar to medication compliance and side effects, to be regularly monitored during antidepressant clinical management.
引用
收藏
页码:2414 / 2420
页数:7
相关论文
共 50 条
  • [1] Clinical and Pharmacologic Perspectives on the Treatment of Major Depressive Disorder
    Jefferson, James W.
    CNS SPECTRUMS, 2011, 16 (09) : 191 - 203
  • [2] Treatment for major depressive disorder
    Zhang, X.
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2015, 84 : 81 - 81
  • [3] Urinary neopterin levels in patients with major depressive disorder and panic disorder who do not receive pharmacologic treatment
    Taymur, Ibrahim
    Ozen, Nurper Erberk
    Boratav, Riza Cumhur
    Yaman, Halil
    ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, 2011, 12 (01): : 7 - 12
  • [4] Milnacipran treatment of a terminally ill cancer patient with major depressive disorder
    Sato, K
    Higuchi, H
    Yoshida, K
    Takahashi, H
    Shimizu, T
    Watanabe, J
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2004, 19 (06) : 431 - 432
  • [5] Visual Hallucinations During Duloxetine Treatment in a Patient With Major Depressive Disorder
    Tomita, Tetsu
    Yasui-Furukori, Norio
    Kaneko, Sunao
    CLINICAL NEUROPHARMACOLOGY, 2013, 36 (05) : 175 - 176
  • [6] Patient Functioning, Life Engagement, and Treatment Goals in Major Depressive Disorder
    Correll, Christoph U.
    Ismail, Zahinoor
    McIntyre, Roger S.
    Rafeyan, Roueen
    Thase, Michael E.
    JOURNAL OF CLINICAL PSYCHIATRY, 2022, 83 (05) : 21 - 24
  • [7] Lithium in the Treatment of Major Depressive Disorder
    Tom Bschor
    Drugs, 2014, 74 : 855 - 862
  • [8] Ketamine in the Treatment of Major Depressive Disorder
    Luu, Brent
    Rice, Elizabeth
    Goldin, Philippe
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2020, 16 (03): : 228 - 231
  • [9] Lithium in the Treatment of Major Depressive Disorder
    Bschor, Tom
    DRUGS, 2014, 74 (08) : 855 - 862
  • [10] Treatment guidelines for major depressive disorder
    Hollon, SD
    Shelton, RC
    BEHAVIOR THERAPY, 2001, 32 (02) : 235 - 258